Show simple item record

dc.contributor.authorEmregul, Emelen_US
dc.contributor.authorDavid, Allanen_US
dc.contributor.authorBalthasar, Joseph P.en_US
dc.contributor.authorYang, Victor C.en_US
dc.date.accessioned2006-12-07T16:53:28Z
dc.date.available2006-12-07T16:53:28Z
dc.date.issued2005-12-01en_US
dc.identifier.citationEmregul, Emel; David, Allan; Balthasar, Joseph P.; Yang, Victor C. (2005)."A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studies." Journal of Biomedical Materials Research Part A 75A(3): 648-655. <http://hdl.handle.net/2027.42/48779>en_US
dc.identifier.issn1549-3296en_US
dc.identifier.issn1552-4965en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/48779
dc.description.abstractImmune thrombocytopenic purpura (ITP) is an autoimmune disease that affects thousands of Americans each year. The resulting thrombocytopenia, which develops from destruction of platelets (PLT) by anti-PLT autoantibodies (APAb), is often associated with hemorrhagic complications. Existing therapies are not effective and are associated with significant morbidity. Recently, a new treatment modality using plasmapheresis with a Protein-A column has shown some clinical promise. Yet, although this method would remove the pathogenic APAb, it would also deplete protective antibodies, thereby weakening the body's self-defense system. Because about 80% of patients with ITP develop APAb against the GPIIb/IIIa antigens on PLT, a novel approach of attaching a GPIIb/IIIa-linked bioreactor with an extracorporeal circuit is suggested herein to achieve highly effective/specific APAb removal and overcome shortcomings of plasmapheresis in treating ITP. A hollow fiber-based bioreactor device was fabricated, and GPIIb/IIIa antigens were immobilized onto the inner lumens of the hollow fibers by using the epichlorohydrin activation method. An optimized bioreactor containing a loading of 1.63 mg GPIIb/IIIa/g fibers and adsorption capacity of 1.9 mg 7E3/g fibers was developed. Preliminary proof-of-concept investigation using a 7E3-induced thrombocytopenic rat model (which mimicked clinical ITP) was carried out. A complete (100%) return of PLT counts to their initial levels was observed in rats within 6 h after the GPIIb/IIIa bioreactor treatment. In addition, a rapid restoration of WBC counts in the treated rats was also found. These preliminary findings shed light of promise of using the GPIIb/IIIa bioreactor approach in achieving highly improved ITP therapy. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res, 2005en_US
dc.format.extent207219 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherChemistryen_US
dc.subject.otherPolymer and Materials Scienceen_US
dc.titleA GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studiesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelBiomedical Engineeringen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065en_US
dc.contributor.affiliationumDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065en_US
dc.contributor.affiliationumDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065 ; Victor C. Yang is a Cheung Kong Scholar, School of Chemical Engineering, Tianjin University, Tianjin 300072, China. ; Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065en_US
dc.contributor.affiliationotherDepartment of Pharmaceutics, State University of New York at Buffalo, Buffalo, New York 14200en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/48779/1/30470_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/jbm.a.30470en_US
dc.identifier.sourceJournal of Biomedical Materials Research Part Aen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record